Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for Biofrontera (BFRIW) over the last 6 years, with Q3 2025 value amounting to $1.0 million.

  • Biofrontera's Non-Current Assets fell 3678.23% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 6668.23%. This contributed to the annual value of $1.4 million for FY2024, which is 7115.5% down from last year.
  • Latest data reveals that Biofrontera reported Non-Current Assets of $1.0 million as of Q3 2025, which was down 3678.23% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, Biofrontera's Non-Current Assets ranged from a high of $7.7 million in Q4 2022 and a low of $1.0 million during Q3 2025
  • Over the past 5 years, Biofrontera's median Non-Current Assets value was $4.6 million (recorded in 2023), while the average stood at $4.3 million.
  • As far as peak fluctuations go, Biofrontera's Non-Current Assets soared by 4901.36% in 2021, and later crashed by 7158.37% in 2025.
  • Biofrontera's Non-Current Assets (Quarter) stood at $6.8 million in 2021, then rose by 13.92% to $7.7 million in 2022, then plummeted by 37.28% to $4.9 million in 2023, then plummeted by 71.16% to $1.4 million in 2024, then fell by 28.48% to $1.0 million in 2025.
  • Its Non-Current Assets was $1.0 million in Q3 2025, compared to $1.3 million in Q2 2025 and $1.3 million in Q1 2025.